MHRA jumps into personalized medicine with the ‘preference zone’The U.K. Medicines and Healthcare Products Regulatory Agency has decided to lean into personalized medicine with the adoption of the concept of a “preference zone” for determining when a therapy can and cannot be used for a specific patient, a concept that is liable to lead to more demanding postmarket surveillance.